Literature DB >> 8644765

Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry.

G Finazzi1, V Brancaccio, M Moia, N Ciaverella, M G Mazzucconi, P C Schinco, M Ruggeri, E M Pogliani, G Gamba, E Rossi, F Baudo, C Manotti, A D'Angelo, G Palareti, V De Stefano, M Berrettini, T Barbui.   

Abstract

PURPOSE: To assess the natural history and risk factors for thrombosis in a large cohort of unselected patients with antiphospholipid antibodies. PATIENTS AND METHODS: Three hundred sixty consecutive patients (118 males, 242 females, median age 39 years [range 2 to 78]) fulfilling the currently accepted criteria for diagnosis of lupus anticoagulant (LAC) (n = 326) and/or raised immunoglobulin G anticardiolipin antibodies (IgG ACA) (n = 185) were collected from 16 Italian institutions and prospectively observed for a median of 3.9 years (range 0.5 to 5). Main endpoints were the occurrence of arterial or venous thrombosis, the outcome of pregnancies, and any severe complications leading to hospitalization or death.
RESULTS: Thirty-four patients developed a thrombotic complication, with a total incidence of 2.5% patient-years. Multivariate logistic regression analysis identified two independent risk factors for thrombotic events: a previous thrombosis (RR 4.9; 95% CI, 1.76 to 13.7; P < 0.005) and IgG ACA titer above 40 units (RR 3.66; 95% CI, 1.24 to 10.8; P < 0.01). A total of 28 pregnancies were observed in 25 women and 11 (39%) were abortive. Adverse pregnancy outcomes were significantly more frequent in women with a history of miscarriage or vascular occlusion (9/16, 56%) than in asymptomatic women (2/12, 17%) (P = 0.035). Four patients developed non-Hodgkin's lymphoma during the follow-up. Eighteen patients died. Vascular events and hematological malignancies represented the most frequent causes of death (n = 5 for each).
CONCLUSIONS: The present study shows that: (a) previous thrombosis and ACA titer > 40 U are independent predictors of thrombosis; (b) history of miscarriage or vascular disease is significantly associated with adverse pregnancy outcome; (c) hematological malignancies can develop during follow-up in patients with antiphospholipid antibodies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8644765     DOI: 10.1016/s0002-9343(96)00060-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  59 in total

Review 1.  Clinical trials for the antiphospholipid syndrome.

Authors:  J T Merrill
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

Review 2.  Testing for and clinical significance of anticardiolipin antibodies.

Authors:  S W Reddel; S A Krilis
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

Review 3.  Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations.

Authors:  George K Bertsias; Dimitrios T Boumpas
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

4.  Antiphospholipid Antibody Syndrome.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-09       Impact factor: 3.598

5.  Detection of anticardiolipin antibody IgG by time-resolved fluoroimmunoassay.

Authors:  Yan Ye; Zhigang Hu; Jie Liu; Guoqian Chen; Yaohong Zhou; Lei Yu
Journal:  Clin Rheumatol       Date:  2012-06-10       Impact factor: 2.980

6.  A new Eu(3+)-labeled method for anticardiolipin antibody IgM.

Authors:  Yan Ye; Zhigang Hu; Jie Liu; Guoqian Chen; Yaohong Zhou
Journal:  J Clin Lab Anal       Date:  2014-03-22       Impact factor: 2.352

Review 7.  Renal manifestations of the antiphospholipid syndrome.

Authors:  David D'Cruz
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

8.  [21-year-old patient with myocardial infarct, transient cerebral ischemia and thrombocytopenia].

Authors:  A Rank; L Lindner; E Hiller
Journal:  Internist (Berl)       Date:  2003-03       Impact factor: 0.743

Review 9.  Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop?

Authors:  Sinthiya Punnialingam; Munther A Khamashta
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

Review 10.  [Thrombophilias in patients with ischemic stroke. Indication and calculated costs for evidence-based diagnostics and treatment].

Authors:  R Weber; E Busch
Journal:  Nervenarzt       Date:  2005-02       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.